{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:53:02Z","timestamp":1794001982831,"version":"4.8.0"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,7,29]],"date-time":"2009-07-29T00:00:00Z","timestamp":1248825600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Long\u2010term antibody responses to 23\u2010valent pneumococcal polysaccharide vaccine (PPV) among HIV\u2010infected patients receiving highly active antiretroviral therapy (HAART) are rarely investigated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Antibody responses to three pneumococcal capsular polysaccharides [Pneumococcal polysaccharide (PPS) 14, 19F and 23F] were assessed among 169 HIV\u2010infected patients who received HAART and 23\u2010valent PPV. Patients were stratified into four groups according to CD4 count at vaccination: group 1, CD4&lt;100\u2003cells\/\u03bcL (<jats:italic>n<\/jats:italic>=35); group 2, CD4 100\u2013199\u2003cells\/\u03bcL (<jats:italic>n<\/jats:italic>=36); group 3, CD4 200\u2013349\u2003cells\/\u03bcL (<jats:italic>n<\/jats:italic>=34); and group 4, CD4\u2265350\u2003cells\/\u03bcL (<jats:italic>n<\/jats:italic>=64). The proportion of patients who achieved increases in antibody titres of twofold or greater from baseline values (responders) was compared among the four groups of patients for five consecutive years after vaccination.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The proportion of responders to the three serotypes was significantly lower among patients in group 1 compared with those in the other three groups during yearly follow\u2010up. Much faster loss of antibody responses was observed in group 1, although the rate of decline varied with the serotypes studied in the four groups. Compared with the nonresponders, more responders had CD4 counts &gt;100\u2003cells\/\u03bcL at vaccination and achieved better virological suppression throughout the 5\u2010year period, while the absolute increases of CD4 cell counts after HAART were not statistically significantly different.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Despite continued increases in CD4 cell counts after HAART, the proportion of HIV\u2010infected patients who maintained antibody responses to PPV declined significantly over the 5\u2010year follow\u2010up period, especially among those who had CD4 counts &lt;100\u2003cells\/\u03bcL at vaccination and who failed to achieve virological suppression.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2009.00744.x","type":"journal-article","created":{"date-parts":[[2009,7,29]],"date-time":"2009-07-29T06:27:50Z","timestamp":1248848870000},"page":"54-63","source":"Crossref","is-referenced-by-count":48,"title":["A 5\u2010year longitudinal follow\u2010up study of serological responses to 23\u2010valent pneumococcal polysaccharide vaccination among patients with HIV infection who received highly active antiretroviral therapy<sup>*<\/sup>"],"prefix":"10.1111","volume":"11","author":[{"given":"C\u2010C","family":"Hung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u2010Y","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u2010T","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u2010Y","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u2010F","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u2010Y","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W\u2010C","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u2010H","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u2010C","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,8]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/162.5.1012"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-132-3-200002010-00003"},{"key":"e_1_2_6_4_2","first-page":"1623","article-title":"Invasive pneumococcal disease in patients infected with HIV","volume":"38","author":"Jordano Q","year":"2004","journal-title":"still a threat in the era of highly active antiretroviral therapy"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1086\/430356"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/529201"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.13.1533"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2008.00546.x"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.17.2633"},{"key":"e_1_2_6_10_2","first-page":"794","article-title":"Pneumococcal disease among human immunodeficiency virus\u2010infected persons","volume":"32","author":"Dworkin MS","year":"2001","journal-title":"incidence, risk factors, and impact of vaccination"},{"key":"e_1_2_6_11_2","first-page":"2006","article-title":"Clinical experience of the 23\u2010valent capsular polysaccharide pneumococcal vaccination in HIV\u20101\u2010infected patients receiving highly active antiretroviral therapy","volume":"22","author":"Hung CC","year":"2004","journal-title":"a prospective observational study"},{"key":"e_1_2_6_12_2","first-page":"e82","article-title":"Effectiveness of polysaccharide pneumococcal vaccine in HIV\u2010infected patients","volume":"45","author":"Penaranda M","year":"2007","journal-title":"a case-control study"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2008.08.032"},{"key":"e_1_2_6_14_2","unstructured":"Adult Prevention and Treatment of Opportunistic Infections Guidelines Working Group.Guidelines for prevention and treatment of opportunistic infections in HIV\u20101\u2010infected adults and adolescents. U.S. Department of Health and Human Services 2008 1\u2013289."},{"key":"e_1_2_6_15_2","first-page":"479","article-title":"Impaired anti\u2010pneumococcal antibody response in patients with AIDS\u2010related persistent generalized lymphadenopathy","volume":"68","author":"Ballet JJ","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.5.983"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1991.tb08146.x"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/165.3.553"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199404000-00008"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.2.340"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.5.1217"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.5.1253"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/499821"},{"key":"e_1_2_6_24_2","first-page":"524","article-title":"Antibodies against pneumococcal polysaccharides after vaccination in HIV\u2010infected individuals","volume":"18","author":"Kroon FP","year":"1999","journal-title":"5-year follow-up of antibody concentrations"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(00)00232-2"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00357-2"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1086\/375841"},{"key":"e_1_2_6_28_2","first-page":"2567","article-title":"Serological response to pneumococcal vaccination in HAART\u2010treated HIV\u2010infected patients","volume":"24","author":"Falco V","year":"2006","journal-title":"one year follow-up study"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.6.2043-2050.2000"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.01.119"},{"key":"e_1_2_6_31_2","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1001\/jama.1987.03390150063035","article-title":"Antibody responses after influenza and pneumococcal immunization in HIV\u2010infected homosexual men","volume":"257","author":"Huang KL","year":"1987","journal-title":"JAMA"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/160.5.826"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/164.4.761"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.1.49"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/172.2.551"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365549850161160"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1086\/368331"},{"key":"e_1_2_6_38_2","first-page":"137","article-title":"Specificity of the antibody response to the pneumococcal polysaccharide and conjugate vaccines in human immunodeficiency virus\u2010infected adults","volume":"11","author":"Feikin DR","year":"2004","journal-title":"Clin Diag Lab Immunol"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282887e91"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0730819100"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20072683"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2009.00744.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2009.00744.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T09:31:34Z","timestamp":1698658294000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2009.00744.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,8]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1468-1293.2009.00744.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2009.00744.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,8]]}}}